Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Biotech
Amgen eyes lupus redemption while cancer candidate struggles
Daxdilimab hit the primary endpoint in a phase 2 trial for discoid lupus, while another gastric cancer trial for bemarituzumab has been halted.
Darren Incorvaia
Feb 4, 2026 6:10am
FDA to ‘carefully shepherd’ CAR-T for autoimmune disease: Prasad
Feb 3, 2026 11:40am
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Dianthus offers up to $1B for China biotech’s autoimmune asset
Oct 16, 2025 10:57am
Kyorin pens $105M pact for Japan rights to Hinge's lupus drug
Oct 1, 2025 6:40am
Royalty bestows Zenas with $300M for autoimmune approval push
Sep 2, 2025 11:07am
